Nexstim Plc Business and Clinical Update Q1 2021
Press release,Helsinki, 22.04.2021, 12.00 pm (EEST)
Nexstim Plc Business and Clinical Update Q1 2021
Nexstim Plc (NXTMH:HEX, NXTMS:STO) ("Nexstim" or "Company") announces the key highlights of the Company’s business and clinical progress during Q1 2021.
CEO Mikko Karvinen’s Business and Clinical Update
Glad to inform that our operational business has had the best start of the year ever while beginning our first full year of executing our renewed strategy. During the first months of 2021, we have continued to invest in the growth of our diagnostic and therapeutic business with the recruitment of two new sales team members to our US organization. At the same time, we are extremely pleased to see that our existing NBS and NBT® System customer base has increased the utilisation rate of our installed base to a record level. High utilization of the systems leads into growing levels of high margin recurring revenue, an important element in our profitable growth strategy.
Parallel to focusing on growth efforts we will actively keep monitoring the COVID-19 pandemic environment. Despite the COVID-19 business environment still present we have continued our work in increasing the numbers of both NBS Systems used for pre-surgical mapping of the brain and NBT® Systems installed mainly for use in the treatment of MDD. The focus has been particularly on the large U.S. market, but also in a targeted manner in the EU. Between January-March 2021, we had delivered a total of 4 new NBS systems and a total of 2 new NBT® Systems. As a result, there were at the end of Q1 2021 a total of 33 NBT® Systems installed worldwide (18 in the U.S. and 15 in Europe and the rest of the world) for the treatment of depression and chronic neuropathic pain.
The clinical year got a great start with news about a new study published in the journal Cancers in January presenting impressive results of nTMS language mapping in a large number of patients1. The study published by a neurosurgical team at Technical University of Munich (TUM) in Germany included 140 consecutive patients with suspected language-eloquent brain tumours. Nexstim SmartFocus® nTMS pre-operative language mapping was performed on all these patients. In a very high number of patients tumour could be removed to the maximum extent, with gross total resection (GTR) achieved in 82.3% of cases.
The clinical news flow continued in March with Nexstim providing encouraging results of the initial pilot study in severe depression at Kuopio University Hospital. Nexstim announced that all 10 patients treated with the accelerated iTBS protocol had completed their 5-day treatment and 7 had completed at least 5 weeks of their planned 12-week follow-up. The 10 patients were treated with shortened treatment sessions to ensure patient safety with the accelerated protocol and no study discontinuations or serious adverse events issues have occurred. All ten patients showed improvement of symptoms on the clinician administered Hamilton Depression Rating Scale (HAMD-17) outcome measure at the end of treatment (mean decrease in score from baseline 37%, p<0.001). 1 of 10 patients (10% had reached clinical remission and 3 of 10 (30%) a clinical response defined as >50% improvement on the measure. As the accelerated treatment protocols and their development are in the core strategic development path of our business, we will continue these trials with an increased number of patients.
In addition to the above the Company reported in March very promising clinical outcomes of the 159 patients who had completed Nexstim SmartFocus® rTMS treatment with Nexstim NBT® system for major depressive disorder (MDD) at participating clinical sites in the U.S. Treatment outcomes of these 159 patients were good: 47.2 % were in remission at end of treatment and 76.1 % had obtained a clinical response. These outcomes are clearly higher than what is usually reported for MDD: In a well-conducted multisite study, remission rates were 26.5-28.7 % and the patient-reported response rates were 41.5-56.4 %2. The patient-reported remission and response rates are also higher than those reported in a large >3800 patient series for patients completing clinical rTMS treatment (remission 29.7-36.2%, response 62.7-70.4%)3. We continue to gather this important clinical outcome data as we aim for a patient data registry of over 200 completed treatment sessions of depression patients before the end of the year 2021.
Finally, I once again thank the shareholders for their trust in the spring 2021 rights issue. We are very happy with the final results of the share issue, and with the funds raised, for the possibility to continue executing our renewed strategy. The Nexstim team will work hard to increase shareholder value over the long-term in the form of stronger competitive advantages, faster growth, and better financial results. While again being optimistic about the year 2021, we will closely continue to monitor the development of the COVID-19 pandemic as we operate our business.
1) Ille S, et al. Non-Invasive Mapping for Effective Preoperative Guidance to Approach Highly Language-Eloquent Gliomas—A Large Scale Comparative Cohort Study Using a New Classiﬁcation for Language Eloquence. Cancers 2021, 13, 207. https://doi.org/10.3390/cancers13020207
2) Carpenter L. et al. Transcranial magnetic stimulation (TMS) for major depression: a multisite, naturalistic, observational study of acute treatment outcomes in clinical practice. Depress Anxiety. 2012 Jul;29(7):587-96. Epub 2012 Jun 11.
3) Sackheim, H. et al. Clinical outcomes in a large registry of patients with major depressive disorder treated with Transcranial Magnetic Stimulation. Journal of Affective Disorders 277 (2020) 65–74.
Further information is available on the website www.nexstim.com, or by contacting:
Mikko Karvinen, CEO
+358 50 326 4101
About Nexstim Plc
Nexstim is a Finnish, globally operating medical technology company. Our mission is to enable personalized and effective therapies and diagnostics for challenging brain diseases and disorders.
Nexstim has developed a world-leading non-invasive brain stimulation technology called SmartFocus®. It is a navigated transcranial magnetic stimulation (nTMS) technology with highly sophisticated 3D navigation providing accurate and personalized targeting of the TMS to the specific area of the brain.
SmartFocus® technology is used in Nexstim’s proprietary Navigated Brain Therapy (NBT®) system, which is FDA cleared for marketing and commercial distribution for the treatment of major depressive disorder (MDD) in the United States. In Europe, the NBT® system is CE marked for the treatment of major depression and chronic neuropathic pain.
In addition, Nexstim is commercializing its SmartFocus® based Navigated Brain Stimulation (NBS) system for diagnostic applications. The NBS system is the only FDA cleared and CE marked navigated TMS system for pre-surgical mapping of the speech and motor cortices of the brain. Nexstim shares are listed on the Nasdaq First North Growth Market Finland and Nasdaq First North Growth Market Sweden.
For more information please visit www.nexstim.com
AttachmentTo view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire
Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire
Equinor ASA: Generalforsamlingen vedtok utbytte på USD 0,12 per aksje for fjerde kvartal 202011.5.2021 20:32:22 CEST | Pressemelding
Generalforsamlingen i Equinor ASA (OSE: EQNR, NYSE: EQNR) godkjente 11. mai 2021 styrets forslag til årsregnskap og årsberetning for Equinor ASA for 2020. Årsregnskap og årsberetning for Equinor ASA og for konsernet for 2020 ble godkjent, og det utdeles et utbytte på 0,12 amerikanske dollar per aksje for fjerde kvartal 2020. Utbyttet for fjerde kvartal 2020 tilfaller aksjeeiere som er registrert i Equinors aksjeeierregister i verdipapirsentralen (VPS) per utløpet av 14. mai 2021 (”Eierregisterdatoen”). Forutsatt ordinært oppgjør i VPS innebærer dette at man må være aksjeeier per 11. mai 2021 for å ha rett til utbytte. Utbytte til rettighetshavere under ADR-programmet (American Depository Receipts) i USA tilfaller også rettighetshavere per 11. mai 2021. Aksjene vil bli handlet eks. utbytte på Oslo Børs fra og med 12. mai 2021. På New York Stock Exchange vil ADR’er bli handlet eks. utbytte fra og med 13. mai 2021. Aksjeeiere med aksjer som handles på Oslo Børs vil motta sitt utbytte i no
Equinor ASA: Annual general meeting approved dividend of USD 0.12 per share for fourth quarter 202011.5.2021 20:32:22 CEST | Press release
On 11 May 2021, the annual general meeting (AGM) of shareholders in Equinor ASA (OSE: EQNR, NYSE: EQNR) approved the annual report and accounts for Equinor ASA for 2020, as proposed by the board of directors. The annual accounts and the annual report for Equinor ASA and the Equinor group for 2020 were approved, and a dividend of US dollar (”USD”) 0.12 per share will be distributed for the fourth quarter of 2020. The fourth quarter 2020 dividend accrues to the shareholders as registered in Equinor’s shareholder register with the Norwegian Central Securities Depository (VPS) as of expiry of 14 May 2021 (the ”Record Date”). Subject to ordinary settlement in VPS, this implies that the right to dividend accrues to shareholders as of 11 May 2021. For US ADR (American Depository Receipts) holders, dividend accrues also as of 11 May 2021. The shares will be traded ex-dividend on the Oslo Stock Exchange (Oslo Børs) from and including 12 May 2021. On New York Stock Exchange, the ADRs will trade
Kommuniké från årsstämma i Corline Biomedical AB (publ)11.5.2021 19:47:30 CEST | Pressemelding
Idag den 11 maj 2021 hölls årsstämma i Corline Biomedical AB (publ). Nedan följer en sammanfattning av de beslut som fattades. Samtliga beslut fattades enhälligt. Fastställande av resultat Bolagsstämman fastställde resultat- och balansräkningarna och beslutade, i enlighet med styrelsens förslag, att resultatet enligt den fastställda resultaträkningen skulle överföras i ny räkning. Någon utdelning lämnas inte. Ansvarsfrihet Bolagsstämman beviljade styrelseledamöterna och verkställande direktören ansvarsfrihet för förvaltningen av Bolagets angelägenheter under räkenskapsåret 2020. Något beslut fattades emellertid inte avseende styrelseordföranden, då han – som enda röstande på bolagsstämman – inte kunde rösta om den egna ansvarsfriheten. Fastställande av antalet styrelseledamöter, styrelsesuppleanter och antalet revisorer Stämman beslutade att styrelsen ska bestå av fem (5) styrelseledamöter samt en (1) styrelsesuppleant. Vidare beslutades att bolaget ska fortsätta ha ett registrerat rev
TGS-NOPEC Geophysical Company ASA (TGS) - Annual General Meeting Held11.5.2021 18:44:31 CEST | Press release
OSLO, Norway (11 May 2021) - The Annual General Meeting of TGS was held on 11 May 2021. All resolutions proposed were approved by the shareholders. The minutes from the Annual General Meeting are attached to this announcement. About TGS TGS provides scientific data and intelligence to companies active in the energy sector. In addition to a global, extensive and diverse energy data library, TGS offers specialized services such as advanced processing and analytics alongside cloud-based data applications and solutions. Forward Looking Statement All statements in this press release other than statements of historical fact are forward-looking statements, which are subject to a number of risks, uncertainties and assumptions that are difficult to predict, and are based upon assumptions as to future events that may not prove accurate. These factors include TGS' reliance on a cyclical industry and principal customers, TGS' ability to continue to expand markets for licensing of data, and TGS' ab
Banque Profil de Gestion SA : Changement d’actionnaire de référence, nouvelle raison sociale et changements au sein du Conseil d’administration11.5.2021 18:21:13 CEST | Press release
Communiqué de presse Banque Profil de Gestion SA : Changement d’actionnaire de référence, nouvelle raison sociale et changements au sein du Conseil d’administration Genève, le 11 mai 2021 – Comme annoncé le 9 février dernier, Banque Profil de Gestion SA (BPDG), son actionnaire actuel de référence (Banca Profilo S.p.A) ainsi que les actionnaires de la société One Swiss Bank SA (OSB) ont signé deux contrats de vente d’actions formalisant, d’une part, le rachat par BPDG de 100% du capital de OSB et, d’autre part, la cession par Banca Profilo SpA des 60.4% d’actions qu’elle détient dans BPDG aux actionnaires actuels de OSB (la «Transaction»). La Transaction impliquera également la fusion subséquente par absorption de OSB par BPDG. Pour rappel, la Transaction est notamment soumise à agrément de la FINMA. Les démarches y relatives sont en cours et l’exécution des deux contrats de vente formalisant la Transaction (le «Closing ») interviendra le 1er juin prochain, sauf objection de la FINMA d’
Brunel AGM 202111.5.2021 18:00:00 CEST | Press release
Amsterdam, 11 May 2021 – Brunel International N.V. (Brunel; BRNL), a global provider of flexible workforce solutions and expertise, today announced the voting results of the Annual General Meeting of Shareholders (AGM) of 11 May 2021. The AGM approved all voting items that were on the agenda. As a result, Jilko Andringa is reappointed as a member of the board of directors for a new term of four years. At the close of the meeting Mr Aat Schouwenaar, chairman of the supervisory board, retired from the supervisory board after having served on the supervisory board for 20 years. Mr Just Spee is reappointed as a member of the Supervisory Board for his second term of four years and will succeed Mr Aat Schouwenaar as chair of the Supervisory Board. Mr Frank van der Vloed is appointed as member of the Supervisory Board for a term of four years. A dividend of €0.30 per share of €0.03 par value has been declared for the 2020 financial year. The dividend, less 15% dividend withholding tax, will b
Outcome of 2021 Shareholders’ Meeting11.5.2021 17:45:00 CEST | Press release
Outcome of 2021 Shareholders’ Meeting Brussels, May 11, 2021, 17:45 CEST - Solvay today held its General Shareholders’ Meeting virtually. Shareholders voted in favor of all the resolutions proposed. More specifically, they approved the payment of a gross dividend of €3.75 per share for the year 2020. After deduction of the interim dividend of €1.50 gross per share, paid in January 2021, the balance amounts to €2.25 gross per share (€1.575 net, after deduction of 30% of withholding tax). Calendar of payment related to the 2020 final dividend May 17, 2021: ex-date May 18, 2021: record date May 19, 2021: payment date During the meeting, shareholders approved the reelection for a four year mandate for Nicolas Boël, Ilham Kadri, Bernard de Laguiche, Françoise de Viron and Agnès Lemarchand and for a three year mandate for Hervé Coppens d'Eeckenbrugge. They also approved the appointment of two new directors, Dr. Wolfgang Colberg and Edouard Janssen, to replace Amparo Moraleda and Evelyn du Mo